PART I . Business Overview We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs. We are focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be...
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001833214-26-000003 | EDGAR | 102K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-046994 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0000950170-24-038219 | EDGAR | — |
| 2023-04-14 | 2022-12-31 | 0001437749-23-010343 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0000950170-22-004935 | EDGAR | — |
| 2021-04-02 | 2020-12-31 | 0001493152-21-007884 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-336783 | EDGAR | — |
| 2025-11-14 | 2025-09-30 | 0001193125-25-280572 | EDGAR | 34K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104566 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000950170-25-067554 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122443 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094084 | EDGAR | — |
| 2024-05-20 | 2024-03-31 | 0000950170-24-062367 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-063076 | EDGAR | — |
| 2023-08-21 | 2023-06-30 | 0001437749-23-024224 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001437749-23-014634 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025094 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0000950170-22-016221 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001193125-26-114730 | EDGAR | 28K words |
| 2026-03-10 | 0001193125-26-099376 | EDGAR | — |
| 2026-01-12 | 0001193125-26-010515 | EDGAR | — |
| 2026-01-07 | 0001193125-26-005487 | EDGAR | — |
| 2025-12-29 | 0001193125-25-335267 | EDGAR | — |
| 2025-09-30 | 0001193125-25-225119 | EDGAR | — |
| 2025-09-26 | 0001193125-25-220721 | EDGAR | — |
| 2025-07-21 | 0000950170-25-097078 | EDGAR | — |
| 2025-07-17 | 0000950170-25-096645 | EDGAR | — |
| 2025-02-05 | 0000950170-25-014627 | EDGAR | — |
125 total filings indexed. 97 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001833214 |
| Ticker | SABS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.sab.bio |
| Listed | 2021-10-22 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/SABS (~200 tokens, structured JSON with cryptographic provenance)